Cargando…

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis

Postmenopausal osteoporosis increases susceptibility to low-trauma fractures due to reduced bone volume and microarchitectural deterioration. Daily nitrogen-containing bisphosphonates have shown antifracture efficacy in many studies and are the most commonly prescribed treatment for women with postm...

Descripción completa

Detalles Bibliográficos
Autores principales: Moro-Álvarez, María J, Díaz-Curiel, Manuel
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546467/
https://www.ncbi.nlm.nih.gov/pubmed/18686745
_version_ 1782159203461234688
author Moro-Álvarez, María J
Díaz-Curiel, Manuel
author_facet Moro-Álvarez, María J
Díaz-Curiel, Manuel
author_sort Moro-Álvarez, María J
collection PubMed
description Postmenopausal osteoporosis increases susceptibility to low-trauma fractures due to reduced bone volume and microarchitectural deterioration. Daily nitrogen-containing bisphosphonates have shown antifracture efficacy in many studies and are the most commonly prescribed treatment for women with postmenopausal osteoporosis. However, optimal efficacy is often not achieved due to poor patient adherence to medication. Current dosing schedules are often inconvenient or impractical for patients. Poor adherence increases risk of fracture, which itself increases morbidity, healthcare costs and, potentially, mortality. Although weekly rather than daily dosing of bisphosphonates has improved adherence, significant problems remain. Efforts to reduce dosing frequency as a possible means for further improving adherence (compliance and persistence), and therefore treatment outcomes, are ongoing. Risedronate, a third-generation bisphosphonate, has been shown in multiple clinical trials to reduce fracture risk and improve bone mineral density in postmenopausal women with osteoporosis. Risedronate has a specific structure and set of characteristics that enable less frequent dosing. This paper reviews the structure of risedronate, and how this translates into high antiresorptive potency, favorable bone binding, persistence in bone, and good tolerability that permits less frequent dosing. The paper also reviews the clinical evidence for risedronate, demonstrating the viability of less frequent dosing, with its potential benefits for patient convenience and adherence to therapy. Two equivalence or non-inferiority bridging studies have demonstrated the option of novel risedronate dosing regimens. These studies are reviewed to demonstrate the efficacy and safety of two different monthly regimens of risedronate in the treatment of postmenopausal osteoporosis: 75 mg on 2 consecutive days a month and 150 mg once a month. Data for oral risedronate 150 mg once a month are limited to 1 year’s treatment duration. In previous clinical trials, patients receiving risedronate 5 mg daily have been followed for up to 7 years, with no evidence of loss of effectiveness. Risedronate 150 mg once a month has a comparable efficacy and safety to daily doses in the treatment of postmenopausal osteoporosis. These additional treatment options with risedronate provide easier dosing alternatives for patients.
format Text
id pubmed-2546467
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-25464672009-05-20 Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis Moro-Álvarez, María J Díaz-Curiel, Manuel Clin Interv Aging Review Postmenopausal osteoporosis increases susceptibility to low-trauma fractures due to reduced bone volume and microarchitectural deterioration. Daily nitrogen-containing bisphosphonates have shown antifracture efficacy in many studies and are the most commonly prescribed treatment for women with postmenopausal osteoporosis. However, optimal efficacy is often not achieved due to poor patient adherence to medication. Current dosing schedules are often inconvenient or impractical for patients. Poor adherence increases risk of fracture, which itself increases morbidity, healthcare costs and, potentially, mortality. Although weekly rather than daily dosing of bisphosphonates has improved adherence, significant problems remain. Efforts to reduce dosing frequency as a possible means for further improving adherence (compliance and persistence), and therefore treatment outcomes, are ongoing. Risedronate, a third-generation bisphosphonate, has been shown in multiple clinical trials to reduce fracture risk and improve bone mineral density in postmenopausal women with osteoporosis. Risedronate has a specific structure and set of characteristics that enable less frequent dosing. This paper reviews the structure of risedronate, and how this translates into high antiresorptive potency, favorable bone binding, persistence in bone, and good tolerability that permits less frequent dosing. The paper also reviews the clinical evidence for risedronate, demonstrating the viability of less frequent dosing, with its potential benefits for patient convenience and adherence to therapy. Two equivalence or non-inferiority bridging studies have demonstrated the option of novel risedronate dosing regimens. These studies are reviewed to demonstrate the efficacy and safety of two different monthly regimens of risedronate in the treatment of postmenopausal osteoporosis: 75 mg on 2 consecutive days a month and 150 mg once a month. Data for oral risedronate 150 mg once a month are limited to 1 year’s treatment duration. In previous clinical trials, patients receiving risedronate 5 mg daily have been followed for up to 7 years, with no evidence of loss of effectiveness. Risedronate 150 mg once a month has a comparable efficacy and safety to daily doses in the treatment of postmenopausal osteoporosis. These additional treatment options with risedronate provide easier dosing alternatives for patients. Dove Medical Press 2008-06 2008-06 /pmc/articles/PMC2546467/ /pubmed/18686745 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Moro-Álvarez, María J
Díaz-Curiel, Manuel
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
title Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
title_full Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
title_fullStr Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
title_full_unstemmed Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
title_short Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
title_sort risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546467/
https://www.ncbi.nlm.nih.gov/pubmed/18686745
work_keys_str_mv AT moroalvarezmariaj risedronateoncemonthlyapotentialnewregimenforthetreatmentofpostmenopausalosteoporosis
AT diazcurielmanuel risedronateoncemonthlyapotentialnewregimenforthetreatmentofpostmenopausalosteoporosis